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Abstract: Abstract
The use of thyreostats in livestock is strictly forbidden by European legislation since
1981. The investigation of thyreostats is commonly performed by their detection as
derivatives with 3-iodobenzylbromide. Although it leads advantages, the derivatisation
procedure can generally cause a decrease in analyte concentrations. With the aim of
simplifying the analysis of five thyreostats in both bovine urine and in thyroid glands,
two methods were developed without the derivatisation step. Salting-out assisted
liquid-liquid extraction was carried out for both matrices, followed by high-performance
liquid chromatography coupled with triple-quadrupole mass spectrometry analysis. The
methods were validated in agreement with the guidelines of Commission Decision
2002/657/EC. For all the thyreostats evaluated, satisfactory results were achieved; the
recovery was within 96% to 104% for both the matrices, while precision (coefficient of
variation) was less than 20% for urine and 21% for thyroid glands. The limits of
decision and capacities of detection for all the compounds were lower than the
recommended values of 10 μg L-¹ and 10 μg kg-¹, respectively. In urine, the limits of
decision ranged from 6.9 to 7.3 μg L-¹, and the capacities of detection ranged from 8.5
to 9.7 μg L-¹, while in thyroid glands these values varied from 6.6 μg kg-¹ to 7.4 μg kg-¹
and from 8.0 μg g-¹ to 9.7 μg kg-¹, respectively. The results obtained show that the
methods described are suitable for the direct detection of thyreostats in bovine urine
and thyroid glands.
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 8 
Introduction 9 
Thyreostats are drugs that interfere with the mechanism involved in the synthesis of thyroid hormones and cause a 10 
condition of deficiency of circulating thyroxine (T4) and triiodothyronine (T3) [1, 2], whose production and release are 11 
controlled by the hypothalamus–anterior pituitary axis. The hypothalamus secretes thyrotropin-releasing hormone (TRH), 12 
which in turn stimulates the anterior pituitary gland to release thyroid-stimulating hormone (TSH) that induces the 13 
production of T3 and T4 by the thyroid, which releases them into the bloodstream. These hormones activate the nuclear 14 
transcription of a large number of genes, thus causing the synthesis of enzymes, as well as structural and transport proteins. 15 
This leads to an increase in metabolism and maintains the physical and psychological development of the organism. The 16 
administration of thyreostats causes an improvement in bodyweight gain mainly due to increased absorption and 17 
extracellular retention of water in the edible tissues and in the gastrointestinal tract [3]. Thyreostats are polar amphoteric 18 
thionamides with a heterocyclic tautomeric structure, and are mostly derived from thiouracil and mercapto-imidazole. 19 
The sequence consisting of nitrogen–carbon–sulphur, known as thioamide, is considered responsible for the thyroid-20 
inhibiting activity (Fig. 1). The best known thyreostatic drugs include the very potent thyroid-inhibiting compounds 2-21 
thiouracil (TU), 6-methyl-2-thiouracil (MTU), 6-propyl-2-thiouracil (PTU), 6-phenyl-2-thiouracil (PhTU) and 1-methyl-22 
2-mercapto-imidazole (tapazole, TAP) [4-6]. The chemical structures of these substances are shown in Figure 1. 23 
The fraudulent use of thyreostats produces low quality meat. Moreover, the edible tissues derived from treated 24 
animals might represent a potential risk to the consumer’s health due to the presence of residues and their teratogenic and 25 
carcinogenic effects [7-11]. 26 
In 1981, the European Union banned their use in animal production both as growth promoters and therapeutic 27 
agents [12] and classified them as “substances having anabolic effects and unauthorized substances” belonging to the 28 
group A2 as described by the Council Directive 96/23/CE [13]. However, a relationship between the presence of 29 
Brassicaceae in feed and thiouracil in urine has been demonstrated by Pinel et al. [9], Vanden Bussche et al. [14] and 30 
Kiebooms et al. [15, 16]. The Community Reference Laboratories (CRLs) in 2007 proposed a recommended 31 
concentration of 10 μg L-1 in urine and 10 μg kg-1 in thyroid tissue for the purpose of control, as “low concentrations of 32 
thiouracil have been detected in bovine animals fed with cruciferous plants, however there is scientific evidence showing 33 
that levels above 10 ppb in urine cannot be linked to natural origin due to this contamination” [17]. Recently, Wauters et 34 
al. reported concentrations of up to 18.2 μg L-1 in the 99% percentile from 3894 bovines and they suggested that the 35 
recommended concentration should be increased to 30 μg L-1 [18]. In fact, the 2015 Italian National Residue Plan already 36 
provides this concentration as the limit of detection for thyreostats in urine [19]. 37 
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Thyreostats analyses typically consist of separation methods based on gas or liquid chromatography associated 38 
with a mass spectrometry system of detection. Normally, the extraction of the substances is carried out by using polar 39 
solvents more suitable to the chemical characteristics of the thyreostats, such as methanol, acetonitrile or ethyl acetate. 40 
Further steps of purification or clean-up with different kinds of solid-phase extraction (SPE) have been reported. Due to 41 
the low molecular mass and high polarity of the thyreostats, several authors have proposed a derivatisation step before or 42 
after the clean-up, mainly by using 3-iodobenzylbromide (3-IBBr) in the case of HPLC-MS/MS analysis [6]. In the case 43 
of GC methods, derivatisation is an unavoidable step in order to convert the analytes into volatile compounds. When 44 
HPLC is applied as the separation technique, analytes may be derivatised and, in the analysis of thyreostats, this procedure 45 
induces the stabilisation of the chemical structure of the molecule in a specific and single tautomeric form, the reduction 46 
of the molecular polarity in order to increase the separation characteristics on the reversed-phase column in the case of 47 
HPLC-MS detection, and an increase in the molecular mass [20]. The low molecular mass, particularly, could be disturbed 48 
by the chemical noise. In term of sensitivity, the derivatisation leads to an improvement of the signal to noise ratio, and 49 
subsequently of the detection capabilities [21]. Despite these advantages, the derivatisation procedure can generally cause 50 
a loss in analyte concentrations. Furthermore, removing derivatisation step simplifies, shortens and makes cheaper the 51 
whole analysis procedure [22, 23]. Based on these observations, we developed the extraction without derivatisation of the 52 
five above-mentioned thyreostats in bovine urine and thyroid glands followed by a sensitive, specific and reproducible 53 
HPLC-MS/MS analysis. For the full identification and quantification of the analytes, the criteria established in the 54 
2002/657/EC Commission Decision were followed and the decision limit (CCα) and the detection capability (CCβ) were 55 
calculated according to the matrix calibration curve procedure as clarified in the document SANCO/2004/2726 rev. 4 [24, 56 
25]. 57 
 58 
Materials and Methods 59 
Reagents and chemicals 60 
All solvents were of HPLC-MS grade quality and purchased from Fluka (Sigma-Aldrich, St. Louis, MO, USA). Formic 61 
acid (98–100%) was from Riedel-de Haën (Sigma-Aldrich). Ultrapure water was obtained through a Milli-Q system 62 
(Millipore, Merck KGaA, Darmstadt, Germany). KH2PO4 and NaCl were from Sigma-Aldrich. The analytes 2-thiouracil 63 
(TU), 6-methyl-2-thiouracil (MTU), 6-propyl-2-thiouracil (PTU), 6-phenyl-2-thiouracil (PhTU), 2-64 
mercaptobenzimidazole or tapazole (TAP) were acquired from Sigma-Aldrich, as well as 5,6-dimethyl-2-thiouracil 65 
(DMTU), used as internal standard (I.S.). A stock solution of 1 mg mL-1 was prepared by dissolving the compounds in 66 
methanol. Serial dilutions were prepared by diluting the stock solution in the mobile phase, which were then stored at 67 
−40°C.  68 
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Phosphate buffer, prepared by dissolving 0.25 M KH2PO4 in ultrapure water, was adjusted to pH 7 and then 69 
saturated with 0.1% DL‐ dithiothreitol (DTT; Sigma‐ Aldrich) as in Vanden Bussche et al. [11]. 70 
 71 
Sample collection 72 
Urine and thyroid gland samples from Friesian Cows aged 32 to 63 months were collected in a Lombard abattoir after 73 
slaughtering, immediately frozen and taken to the laboratory for storage at –40°C until analysis.  74 
Sample extraction  75 
Urine  76 
One millilitre of bovine urine was transferred to a 15-mL glass tube and spiked with 10 ng of internal standard (DMTU) 77 
in order to give a final concentration of 10 μg L-1, then vortexed and left for 5 minutes to equilibrate. The samples then 78 
underwent denaturation conditions at 65°C for 30 min, after the addition of 1 mL of PBS buffer with 0.1% DTT at pH 7. 79 
NaCl (2 g) was added to the solution to mixture as a salting-out reagent.  80 
The extraction was performed by twice repeating these steps: addition of 5 mL tert-butyl methyl ether, 81 
centrifugation at 2000 x g for 5 min at 4°C, and collection and transfer of the upper organic layer to a 10-mL polypropylene 82 
tube. The extract was dried under vacuum in a rotary evaporator apparatus (Heidolph Instruments GmbH & Co., 83 
Schwabach, Germany) at a temperature of 40°C. The residue was dissolved in 200 µL of the mobile phase (methanol: 84 
0.1% aqueous formic acid, v/v 50:50) and transferred to vials for HPLC. The injection volume was 10 µL. 85 
Thyroid gland  86 
The thyroid gland samples were minced with surgical scissors and homogenised. The sample (1 g) was weighed in a 87 
polypropylene tube and 10 ng of internal standard (DMTU) were added, and then the sample was vortexed and left for 5 88 
minutes to equilibrate, then 5 mL of methanol was added. The samples were vortexed, placed in an ultrasonic bath for 10 89 
min and then centrifuged at 2000 x g at 4°C for 10 min. The organic liquid supernatant was then filtrated and transferred 90 
to a 15-mL glass tube and 5 mL of PBS buffer with 0.1% DTT at pH 7 were added. The samples underwent denaturation 91 
conditions at 65°C for 30 min. To carry out the extraction of the analytes, 2 x 10 mL of Tert-butyl methyl ether and 4 g 92 
of NaCl (used as a salting-out reagent) were added to the solution. The sample was centrifuged at 2000 x g for 5 min at 93 
4°C. The upper organic layer was collected and transferred to a 50-mL glass evaporating flask. Lastly, the extracts were 94 
combined and dried under vacuum in a rotary evaporator apparatus at 40°C. The residue was dissolved in 200 µL of the 95 
mobile phase and transferred to vials for the autosampler. The injection volume was 10 µL. 96 
 97 
HPLC-MS/MS analysis 98 
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A Synergi Hydro RP reverse-phase HPLC column C18 (150 x 2.0 mm, i.d. 4 µm) with a C18 4 x 3.0 mm guard column 99 
(Phenomenex, Torrance, CA, USA) at a column oven temperature of 30oC was used for the separation, which was 100 
performed by an HPLC system that included a Surveyor MS quaternary pump with a degasser, a Surveyor AS autosampler 101 
with a column oven, and a Rheodyne valve with a 20-μl sample loop (Thermo Fisher Scientific, San Jose, CA, USA). 102 
The mobile phase consisted of 0.1% aqueous formic acid (solvent A) and methanol (solvent B), and the flow rate was set 103 
at 200 L/min. The gradient program is shown in Table 1. The overall run time was 30 minutes. The HPLC system was 104 
connected to a TSQ Quantum (Thermo Fisher Scientific, San Jose, CA, USA) triple-quadrupole mass spectrometer with 105 
an electrospray interface (ESI) set in the positive (ESI+) ionization mode. The acquisition was made in the multiple 106 
reaction-monitoring (MRM) mode. The specific acquisition parameters of all the analytes were optimised by means of 107 
direct infusion of standard solutions of the analytes at a concentration of 1 g mL-1, a flow rate of 50 L min-1 and a flow 108 
rate of the MS pump of 100 μL min-1. The capillary voltage was 3.2 kV; the capillary temperature was 340°C; nitrogen 109 
was used as the sheath and auxiliary gas at 30 and 10 arbitrary units, respectively, and argon as the collision gas at 1.5 110 
mTorr; peak resolution was 0.70 Da FWHM. The parent ions, product ions, and collision energy values for each analyte 111 
are shown in Table 2. The scan time for each monitored transition was 0.1 s and the scan width was 0.5 amu. The mass 112 
spectrometer data acquisition and processing were carried out using Xcalibur™ 2.0.7 SP1 software from Thermo Fisher 113 
Scientific Inc. 114 
 115 
Method validation  116 
The HPLC-MS/MS method was validated according to the guidelines of Commission Decision 2002/657/EC [24]. MS 117 
identification criteria were verified throughout the validation study by monitoring relative retention times, signal-to-noise 118 
ratios (S/N) and ion ratios. The instrumental linearity was evaluated through calibration curves in solvent at six levels, 119 
(1.0, 5.0, 10, 20, 50, 80, 100 μg L-1) and 10 μg L-1 of DMTU as I.S. 120 
The method validation parameters were determined with fortified blank urine and thyroid gland samples at three 121 
concentration levels (5.0, 10, 15 μg L-1  and μg kg-1) in six replicates on three different days (6 samples × 3 concentration 122 
levels × 3 series = 54 analyses). Method recovery and precision were evaluated using the matrix curves; recovery is 123 
calculated as ratio between the measured concentration to fortified concentration, corrected by internal standard and 124 
expressed in percentage; precision is calculated in terms of intra- and inter-day repeatability expressed as the coefficient 125 
of variability (CV). The same data from the matrix calibration curves were used to calculate the decision limit (CCα) and 126 
the detection capability (CCβ) according to the matrix validation curve procedure described in the Commission Decision 127 
2002/657/EC and clarified in the document SANCO/2004/2726-rev. 4 [24, 25].  128 
 129 
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Results and Discussion 130 
Sample preparation 131 
Despite the diversity of the matrices analysed, we carried out two similar methods to prepare urine and thyroid glands in 132 
order to have the same steps for each matrix.  133 
A preliminary denaturation step of matrix proteins was carried out to disrupt the protein–thyreostat interaction, 134 
as reported by Vanden Bussche et al. [11], through the cleavage of the disulfide bonds of the proteins by the addition of 135 
a reducing agent, such as DTT. Differently from the above mentioned study, which considered only urine, we adopted 136 
this step for both urine and thyroid glands, with a ten-time-lower concentration of DTT. 137 
The polarity of the thyreostats requires the use of an organic polar solvent to extract them from the matrices: we 138 
evaluated the applicability of different solvents by several tests using ethyl acetate, chloroform and tert-butyl methyl 139 
ether. Comparing the signal intensity of the analytes extracted with the three different solvents, tert-butyl methyl ether 140 
was chosen as the best solvent for the extraction. The poorest results were obtained by the extraction performed with ethyl 141 
acetate by which we could not extract most of the thyreostats. 142 
In order to facilitate the phase separation and to reduce the miscibility of the analytes in the aqueous phase, this 143 
protocol adopted the approach of salting-out-assisted liquid–liquid extraction (SALLE), adding salt (NaCl) prior to the 144 
liquid–liquid extraction to favour the transfer of the analytes into the organic solvent [26-28]. 145 
 146 
Method validation 147 
The analytical procedures developed were subjected to the validation process according to the Commission Decision 148 
2002/657/EC and clarified in the document SANCO/2004/2726-rev. 4 [24, 25]. 149 
The HPLC–MS/MS-reconstructed chromatograms of the thyreostats in urine and thyroid glands are shown in 150 
Figure 2. DMTU as the internal standard (10 μg L-1) is also reported. The analytes were detected and confirmed based on 151 
their proper relative retention times and their ion ratios. The relative retention times were within a tolerance limit of 2.5% 152 
and the relative ion intensities were within the maximum permitted tolerances [24]. The chromatograms in Figure 3 show 153 
the absence of interference peaks at the expected retention times of the thyreostats, hence illustrating a good specificity 154 
and selectivity of the method. 155 
For the HPLC-MS/MS confirmation of substances listed in Group A of Annex I of Directive 96/23/EC [13], a 156 
minimum of four identification points (IPs) is required [24]. In the present work, we monitored five products ions with 157 
the highest intensity. Each one of the five product ions is equal to 1.5 IPs, making a total of 7.5 IPs. The ion giving the 158 
highest signal-to-noise ratio was selected for the quantification. The MRM transition intensities were compliant with the 159 
maximum tolerances permitted. The parameters obtained for the method validations are given in Tables 3, 4 and 5. 160 
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Linearity was verified by using squared correlation coefficients (r2): The regression coefficients of the curves that were 161 
built to check the instrumental linearity were higher than 0.982, which indicates a satisfactory linearity for all the analytes. 162 
Good linearities were also achieved in urine and in thyroid glands and showed values higher than 0.978 and 0.973, 163 
respectively, thus demonstrating a suitable and adequate correlation between the concentration and the acquired response 164 
in the sample for both matrices. The precision of the method, which was calculated by applying one-way analysis of 165 
variance (ANOVA), was evaluated in terms of intra- and inter-day repeatability, and is expressed as the coefficients of 166 
variation (CV) from the replicate samples. Their values were lower than 23%, as proposed by Thompson [29], 167 
demonstrating an acceptable precision for the method. The recoveries showed good values ranging from 96% to 104% in 168 
urine and from 96% to 104% in thyroid glands. The results regarding the precision, even if similar, are not comparable 169 
with the results obtained by Abuìn et al [22, 30], who developed methods for the detection of underivatised thyreostats in 170 
thyroid, because of the lower concentrations used in this paper. The decision limit (CCα) and detection capability (CCβ) 171 
are very important, debated and decisive points to evaluate. For the estimation of these values, the document of the 172 
Commission Decision 2002/657/EC [24] explains both the definition and procedure. However, the approach proposed in 173 
the document to evaluate these limits – based on the extrapolation of the calibration curve procedure according to ISO 174 
11843 – may lead to an underestimation of the parameters, as already explained by Galarini et al. [31] and other authors 175 
[32-33]. 176 
Therefore, CCα (and, consequently, CCβ) was determined using a parallel extrapolation to the x-axis at the 177 
lowest experimental concentration as clarified in the document SANCO/2004/2726-rev. 4 [25]. Decision limits achieved 178 
with this approach were thus experimentally determined, and therefore not underestimated. A comparison with previously 179 
published data concerning the detection of non-derivatised thyreostats should consider the differences in the method of 180 
CCα determination. Table 5 shows the obtained CCα and CCβ values, which are lower than the minimum required 181 
performance limits (MRPLs) proposed in the CRL guidance document of 2007 in urine and in thyroid glands [17]. 182 
Moreover, the TAP analytical limits are lower than those reported in literature for the two matrices, such as MTU in the 183 
thyroid gland [11, 22, 30, 34]. Finally, it is worth noting that the validation parameters obtained with our method are 184 
comparable between the two different matrices. 185 
 186 
Conclusion 187 
The methods for the simultaneous direct identification and quantification of five thyreostats without derivatisation in both 188 
urine and thyroid gland samples were specific and sensitive. Moreover, the validated methods guarantee a better 189 
performance for TAP in both matrices than those reported in the literature. The choice to develop a method without 190 
derivatisation and clean-up steps was made due to the advantages in terms of costs and the time of analysis. The 191 
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simultaneous determination of five thyreostats in two matrices using similar methods could be useful to make comparative 192 
analyses more reliable, because the process variables are the same for urine and thyroid glands.  193 
Furthermore, the measurement of the endogenous TU in urine and thyroid is possible as the analytical limits are 194 
all below 10 μg L-1 and 10 μg kg-1, and particularly considering that the CCα – which was determined as clarified by the 195 
document SANCO/2004/2726-rev. 4 [25] – is not an estimate, but an experimentally verified concentration with all the 196 
characteristics required by the Commission Decision 2002/657/EC [24] for a substance to be quantified.  197 
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Table 1. Gradient table for HPLC method 313 
 314 
Time (min) Eluent A (%) Eluent B (%) 
Flow rate 
(L min-1) 
0 90 10 200 
2 90 10 200 
20 30 70 200 
24 10 90 200 
27 90 10 200 
30 90 10 200 
A: 0.1% aqueous formic acid; B: methanol  
 315 
  316 
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Table 2. MS/MS conditions for the MRM acquisitions of analytes and the internal standard. Ions for quantification are 317 
in bold.  318 
 319 
Analyte 
Precursor ion 
 [M-H]+ 
(m/z) 
Product ionsCE 
(m/z) 
ESI 
TAP 115 5622, 5720, 7417, 8317, 8816 (+) 
TU 128 5735, 6034, 7017, 8327, 11116 (+) 
MTU 143 6032, 7234, 8417, 8623, 12616 (+) 
PTU 171 6035, 6726, 8627, 11219, 15417 (+) 
PhTU 205 7741, 8627, 10326, 10525, 14619 (+) 
DMTU (I.S.) 157 6035, 7229, 8622, 9818, 14016 (+) 
I.S.: internal standard 
CE (eV): collision energy 
  320 
 321 
  322 
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Table 3. Analytical performance (method trueness and precision) data for thyreostat determination in urine. 323 
 324 
Analyte 
Concentration level Recovery % Repeatability 
(μg/L) (n = 18) 
intra-day 
(CV; n = 6) 
inter-day 
(CV; n = 18) 
 5 99 8 20 
TAP 10 101 5 19 
 15 100 5 8 
     
 5 104 15 20 
TU 10 98 10 11 
 15 101 5 5 
     
 5 104 6 19 
MTU 10 96 9 20 
 15 101 7 9 
     
 5 104 12 19 
PTU 10 96 7 16 
 15 101 5 7 
     
 5 100 11 16 
PhTU 10 100 5 13 
 15 100 3 5 
     
CV: coefficient of variation 
  325 
  326 
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Table 4. Analytical performance (method trueness and precision) data for thyreostat determination in thyroid glands. 327 
 328 
Analyte 
Concentration level Recovery % Repeatability 
(μg/kg) (n = 18) 
intra-day 
(CV; n = 6) 
inter-day 
(CV; n = 18) 
 5 104 7 19 
TAP 10 96 10 20 
 15 101 8 10 
     
 5 101 15 21 
TU 10 99 9 17 
 15 100 7 9 
     
 5 99 14 17 
MTU 10 103 9 10 
 15 103 9 18 
     
 5 102 12 20 
PTU 10 98 6 17 
 15 101 8 9 
     
 5 100 12 14 
PhTU 10 100 9 12 
 15 100 9 9 
     
CV: coefficient of variation 
  329 
 330 
  331 
17 
 
Table 5. Decision limits (CCα) and detection capabilities (CCβ) calculated for thyreostats in urine and in thyroid glands. 332 
 333 
Analyte CCα  
(μg L-1 and μg kg-1) 
CCβ  
(μg L-1 and μg kg-1) 
 Urine Thyroid gland Urine Thyroid gland 
TAP 7.3 7.3 9.7 9.7 
TU 7.3 7.4 9.2 9.7 
MTU 7.2 7.0 9.5 8.7 
PTU 7.2 7.4 9.2 9.6 
PhTU 6.9 6.6 8.5 8.0 
 
334 
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Fig. 1. Chemical structure of thyreostats. TU (2-thiouracil), MTU (6-methyl-2-thiouracil), PTU (6-propyl-2-thiouracil), 335 
PhTU (6-phenyl-2-thiouracil), TAP (1-methyl-2-mercapto-imidazole; tapazole), DMTU (5,6-dimethyl-2-thiouracil; 336 
internal standard). 337 
Fig. 2. HPLC-MS/MS chromatograms and ion spectra of a blank urine (A) and a thyroid gland (B) sample spiked with 338 
thyreostats at a final concentration of 5 μg L-1 or μg kg-1, respectively. TU (2-thiouracil), MTU (6-methyl-2-thiouracil), 339 
PTU (6-propyl-2-thiouracil), PhTU (6-phenyl-2-thiouracil), TAP (1-methyl-2-mercapto-imidazole; tapazole). The 340 
concentration of DMTU (5,6-dimethyl-2-thiouracil; internal standard) is 10 μg L-1 or μg kg-1, respectively. 341 
Fig. 3. HPLC-MS/MS chromatograms of a blank urine (A) and a thyroid gland (B) sample, showing the absence of 342 
interfering compounds. TU (2-thiouracil), MTU (6-methyl-2-thiouracil), PTU (6-propyl-2-thiouracil), PhTU (6-phenyl-343 
2-thiouracil), TAP (1-methyl-2-mercapto-imidazole; tapazole).  344 
 345 
Figure 1 Click here to download Figure fig 1.tif 
Figure 2 Click here to download Figure fig 2.tif 
Figure 3 Click here to download Figure fig 3.tif 
